138736-92-2Relevant articles and documents
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
-
Paragraph 1233; 1236; 1237, (2019/02/13)
The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Synthesis of a new chiral bisphosphine ligand, MOCBP, and its use in rhodium(I)-catalyzed asymmetric hydrogenation of a cyclic enamide
Morimoto,Nakajima,Achiwa
, p. 75 - 78 (2007/10/02)
A new chiral bisphosphine ligand (6) bearing a cyclobutane framework was readily prepared by using diastereoselective [2 + 2] cycloaddition. Its rhodium(I) complex was found to be an efficient catalyst for the asymmetric hydrogenation of a cyclic enamide, N-acetyl-1-methylene-1,2,3,4-tetrahydroisoquinoline (9), affording (R)-(-)-N-acetylsalsolidine (10) in up to 80.6% ee.